



Your PepMix™ of Infectious Diseases Antigens

> PepMixes™ are antigen-spanning peptide pools for T-cell assays

Adenovirus

- HadV-3 (hexon protein)
- HadV-5 (penton protein)

BKV

- capsid proteins (VP1, VP2, VP3)
- large T antigen
- small T antigen

EBV

- BMLF1, BMRF1, BRLF1, BZLF1
- EBNA (1, 2, 3a, 3b, 3c, LP)
- GP 340
- LMP1 and LMP2

HCMVA

- IE-1, IE-2, pp65,
- UL28, UL32, UL36, UL40, UL48
- UL55, UL 82, UL 86, UL94, UL99,
- UL103, UL151, UL 153
- US24, US29, US3, US32

HPV

- HPV 16 (Protein E7), HPV 18 (Protein E6)
- HPV 18 (Protein E7), HPV 16 (Protein E6)

HIV

- Con B gag motif

Influenza A

- Hemagglutinin (A/Brisbane/(H1N1))
- Hemagglutinin (A/California/(H1N1))
- Matrix protein 1 (A/California/(H1N1))
- Matrix protein 2 (A/California/(H1N1))
- Matrix protein 1 (strain A/Aichi/(H3N2))
- Matrix Neuroamidase (A/California/(H1N1))
- Nucleocapsid protein (A/Nanchang/(H3N2))

RSV

- protein F
- nucleocapsid protein N

Miscellaneous

- Candida (MP65)
- HBV (large env protein)
- HHV6 (U54)
- Yellow fever (NS24B)

Positive control pools

- HCMVA (IE-1)
- HCMVA (IE-2)
- HCMVA (pp65)
- CEF pool (standard)
- CEF pool (extended)
- CEFT pool
- EF pool

Negative control pools

- Actin, alpha skeletal muscle (ACTS_Human)
- HLA class I Ig-like C1 type domain (Human)
- Myelin-oligodendrocyte glycoprotein (MOG_Human)
- HIV (Con B gag motif)

VZV

- IE-62
- IE-63

PepMix Collection HCMV

- > 19 different PepMixes in one rack for immune response qualification

protected by
European Patents:

EP 1 257 290 & EP 1 051 619

"A Whole Blood Monokine-based Reporter Assay Provides a Sensitive and Robust Measurement of the Antigen-Specific T Cell Response", Chakera et al, J. of Translational Med. (2011); "Live and Inactivated Influenza Vaccines Induce Similar Humoral Responses, but Only Live Vaccines Induce Diverse T-Cell Responses in Young Children", Hoft et al, J. of Inf. Dis. (2011); "Rebound of Residual Plasma Viremia After Initial Decrease Following Addition of Intravenous Immunoglobulin to Effective Antiretroviral Treatment of HIV", Melberg et al, AIDS Res. & Therapy (2011); "Innate and Adaptive Immune Responses Both Contribute to Pathological CD4 T Cell Activation in HIV-1 Infected Ugandans", Eller et al, PLoS ONE (2011)

JPT Peptide Technologies
www.jpt.com
peptide@jpt.com

European Head Office
T +49-30-6392-7878
F +49-30-6392-7888

USA/Canada
T 1-888-578-2660
F 1-888-578-2666

jpt

Innovative Peptide Solutions

Also visit our online ordering portal shop.jpt.com!